Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 10:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 3121–3144 of 10,825 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Developmental Defect Clear all

Conditions: Spinal Muscular Atrophy
Interventions: Not listed
Lead sponsor: Carelon Research; Other
Eligibility: 2 Years to 12 Years
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 16
States / cities: Birmingham, Alabama • Stanford, California • Aurora, Colorado + 13 more

Conditions: Leukemia, Myelodysplastic Syndromes
Interventions: clofarabine, melphalan, gene expression analysis, reverse transcriptase-polymerase chain reaction, flow cytometry, laboratory biomarker analysis, allogeneic hematopoietic stem cell transplantation; Drug · Genetic · Other + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 1 Year to 120 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Duarte, California

Conditions: Interstitial Lung Disease, IPF
Interventions: Retrospective observational study; Other
Lead sponsor: Lahey Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 1,703 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Burlington, Massachusetts

Conditions: Healthy
Interventions: Methylphenidate HCl; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 20 Years to 35 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Cypress, California

Conditions: Turner's Syndrome
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 10 Years and older
Enrollment: 1,017 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Familial Adenomatous Polyposis
Interventions: Personalized surveillance and intervention protocol; Procedure
Lead sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Scoliosis, Kyphosis, Kyphoscoliosis, Spinal Deformity, Spondylosis
Interventions: Not listed
Lead sponsor: Mazor Robotics; Industry
Eligibility: 21 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Heart Defects, Congenital
Interventions: Blalock-Taussig pulmonary artery shunt, Right ventricular to pulmonary artery shunt; Procedure
Lead sponsor: Carelon Research; Other
Eligibility: Not listed
Enrollment: 555 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 12
States / cities: Los Angeles, California • Wilmington, Delaware • St. Petersburg, Florida + 9 more

Conditions: Friedreich's Ataxia
Interventions: Not listed
Lead sponsor: University of Florida; Other
Eligibility: 6 Years to 70 Years
Enrollment: 203 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2030
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions: carboplatin, fludarabine phosphate, thalidomide, topotecan hydrochloride; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Fever
Interventions: Not listed
Lead sponsor: MemorialCare; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 2
States / cities: Long Beach, California • Orange, California

Conditions: Eosinophilic Gastritis, Gastroparesis, Gastric Motility Disorder
Interventions: Not listed
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 18 Years to 59 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: Chicago, Illinois • Bethesda, Maryland • Salt Lake City, Utah

Conditions: Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Relapsed Pediatric Solid Tumor, Refractory Pediatric Solid Tumor, Melanoma, Hepatoblastoma, Hepatocellular Carcinoma, Neuroblastoma, Wilms Tumor
Interventions: Cryoablation Therapy, Nivolumab, Ipilimumab; Procedure · Drug
Lead sponsor: Children's National Research Institute; Other
Eligibility: 1 Year to 39 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Primary Immunodeficiency Diseases (PID)
Interventions: Recombinant human hyaluronidase + immune globulin intravenous; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 16 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 3
States / cities: Centennial, Colorado • North Palm Beach, Florida • Dallas, Texas

Conditions: Duchenne Muscular Dystrophy, Burden, Dependency, Disability Physical, Disease Management, Impairment, Rare Diseases
Interventions: Not listed
Lead sponsor: Jett Foundation, Inc.; Other
Eligibility: 11 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Eagan, Minnesota

Conditions: Fanconi's Anemia, Myelodysplastic Syndromes, Leukemia, Nonlymphocytic, Acute, Leukemia, Lymphocytic, Acute
Interventions: cyclophosphamide, Allogeneic Bone Marrow Transplantation; Drug · Procedure
Lead sponsor: Fairview University Medical Center; Other
Eligibility: 0 Years to 54 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Sickle Cell Disease
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: Not listed
Enrollment: 4,392 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: Epidermolysis Bullosa (EB)
Interventions: SD-101 Dermal Cream (6%), Vehicle (SD-101 0%); Drug
Lead sponsor: Paradigm Therapeutics; Industry
Eligibility: 28 Days to 12 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 4
States / cities: Rancho Santa Margarita, California • Redwood City, California • Philadelphia, Pennsylvania + 1 more

Conditions: Sickle Cell Disease
Interventions: MST-188; Drug
Lead sponsor: Mast Therapeutics, Inc.; Industry
Eligibility: 4 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2015
U.S. locations: 9
States / cities: San Diego, California • Fort Myers, Florida • Hollywood, Florida + 6 more

Conditions: Von Hippel-Lindau Syndrome
Interventions: Ranibizumab; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Renal Cancer, Birt-Hogg-Dube Syndrome
Interventions: Everolimus; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Congenital Heart Disease
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: Not listed
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Neurofibromatosis Type 1, Pediatric Brain Tumor
Interventions: Not listed
Lead sponsor: Washington University School of Medicine; Other
Eligibility: Up to 18 Years
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Post Term Pregnancy, Premature Rupture of Membrane, Fetal Growth Retardation, Oligohydramnios, Gestational Diabetes, High Blood Pressure in Pregnancy
Interventions: Dilapan-S; Device
Lead sponsor: Medicem Technology s.r.o.; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Galveston, Texas

Search by objective public record fields.

A Pilot Study of Biomarkers for Spinal Muscular Atrophy

Clofarabine and High-Dose Melphalan Followed by Donor Stem Cell Transplant in Patients With Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Myelodysplastic Syndromes

ILAs in CT Lung Cancer Screening Population

A Pharmacokinetics and Safety of Methylphenidate HCl in Healthy Japanese Adult Male Volunteers

Turner Syndrome: Genotype and Phenotype

A Personalized Surveillance and Intervention Protocol for Duodenal and Gastric Polyposis in Patients With Familial Adenomatous Polyposis

ADDRESS - Adult Deformity Robotic vs. Freehand Surgery to Correct Spinal Deformity

Comparison of Two Types of Shunts in Infants With Single Ventricle Defect Undergoing Staged Reconstruction--Pediatric Heart Network

Biomarkers in Friedreich's Ataxia

Fludarabine/Carboplatin/Topotecan w/Thalidomide for Relapsed/Refractory AML, CML and MDS

Evaluation of Fever Occurring in Labor in Patients Receiving Epidural Anesthesia

Study of Gastric Motility in Eosinophilic Gastritis

Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors

Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously

Your Voice; Impact of Duchenne Muscular Dystrophy (DMD) on the Lives of Families

Study of Allogeneic Bone Marrow Transplantation Following Cyclophosphamide and Radiotherapy in Patients With Myelodysplastic Syndrome and Acute Leukemia Related to Fanconi's Anemia

Disseminating NIH Evidence Based Sickle Cell Recommendations in North Carolina

Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa

Evaluation of Repeat Administration of Purified Poloxamer 188

Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome

Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer

Influence of Genetic Polymorphisms on Ventricular Structure and Function in Patients With Single Ventricle Anatomy

Neurofibromatosis Type 1 Brain Tumor Genetic Risk

Dilapan-S®: A Multicenter US E-registry